Hong Kong biotechs IPOs face lower valuations after Ascletis flopBiotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Share XHong Kong biotechs IPOs face lower valuations after Ascletis flophttps://pharmaphorum.com/news/hong-kong-biotech-ipos-face-lower-valuations-after-ascletis-flop/
Hepatitis drug wins award for cure rate and efficacyHepatitis C drug Ganovo won a top clinical research award due to its successful performance in a phase Share XHepatitis drug wins award for cure rate and efficacyhttps://pharmaphorum.com/news/hepatitis-drug-wins-award/
